Aytu Biopharma Inc expected to post a loss of 49 cents a share - Earnings Preview

Aytu Biopharma

24/09/2021 21:26

* Aytu Biopharma Inc  AYTU.OQ   AYTU.O  is expected to show a
rise in quarterly revenue when it reports results on September
27. 
* The Englewood, Colorado-based company is expected to report  a
40.6% increase in revenue to $20.9 million from $14.86 million a
year ago, according to the mean estimate from 2 analysts, based
on Refinitiv data. 
​* Refinitiv's mean analyst estimate for Aytu Biopharma Inc is
for a loss of 49 cents per share. For the same quarter last
year, the company reported a loss of 20 cents per share.
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
* The mean earnings estimate of analysts was unchanged in the
last three months. ​
* Wall Street's median 12-month price target for Aytu Biopharma
Inc is $17.5​, about 82.8% above​ its last closing price
of $3.01. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINE    REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        SMARTESTIM  IBES                 MET,    SE %
               ATE®        ESTIMATE             MISSED  
 Mar. 31 2021  -0.31       -0.31      -1.41     Missed  -347.6
 Dec. 31 2020  -0.38       -0.44      -0.70     Missed  -59.1
 Sep. 30 2020  -0.55       -0.55      -0.40     Beat    27.3​
 Jun. 30 2020  -0.50       -0.35      -0.20     Beat    42.9
 Mar.          -1.91​      -2.20      -1.50     Beat    31.8​
 31​ 2020​                                              
 Dec. 31 2019  -2.32       -2.45      -0.10     Beat    95.9​
 Sep. 30 2019  -3.00       -2.75      -3.20     Missed  -16.4
 Jun. 30 2019  -2.50       -3.30      -3.20     Beat    3
 This summary was machine generated September 24 at 20:26 GMT. 
All figures in US dollars unless otherwise stated